Leqembi posts $184M Q2 sales, best quarter since launch, Biogen lifts guidance
read at Endpoints ↗EarningsPositive
Leqembi, the anti-amyloid Alzheimer’s drug co-developed by Eisai and Biogen, generated $184 million in global sales in the second quarter, according to Biogen.
The Q2 figure represents the strongest performance for the drug since it was launched three years ago.
On the back of the sales boost, Biogen said it is raising its guidance for the upcoming period.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Leqembi records best quarter since launch as Biogen raises underlying guidance”
read at Endpoints ↗81 words · retrieved Jul 29
comments(0)
5-min edit window · permanent after that